vs
AMERICAN SHARED HOSPITAL SERVICES（AMS）与BIODESIX INC（BDSX）财务数据对比。点击上方公司名可切换其他公司
BIODESIX INC的季度营收约是AMERICAN SHARED HOSPITAL SERVICES的3.7倍（$28.8M vs $7.7M）。AMERICAN SHARED HOSPITAL SERVICES净利率更高（-8.2% vs -13.8%，领先5.7%）。BIODESIX INC同比增速更快（40.8% vs -14.8%）。BIODESIX INC自由现金流更多（$692.0K vs $-2.7M）。过去两年BIODESIX INC的营收复合增速更高（39.3% vs 21.7%）
美国共享医院服务公司为医疗机构提供放射治疗、立体定向放射外科及诊断成像设备的整体外包解决方案，免除医院高昂的前期资本投入，主要业务覆盖北美，同时服务拉美及部分亚太地区的公立、私立医院客户。
BIODESIX INC是一家专注于肿瘤与感染病领域的分子诊断企业，开发并商业化创新血液检测解决方案，主要服务北美地区的医疗机构、生物制药合作伙伴及患者，核心业务包括辅助临床决策的个性化医疗产品。
AMS vs BDSX — 直观对比
营收规模更大
BDSX
是对方的3.7倍
$7.7M
营收增速更快
BDSX
高出55.5%
-14.8%
净利率更高
AMS
高出5.7%
-13.8%
自由现金流更多
BDSX
多$3.4M
$-2.7M
两年增速更快
BDSX
近两年复合增速
21.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $7.7M | $28.8M |
| 净利润 | $-631.0K | $-4.0M |
| 毛利率 | 11.7% | — |
| 营业利润率 | -18.1% | -6.8% |
| 净利率 | -8.2% | -13.8% |
| 营收同比 | -14.8% | 40.8% |
| 净利润同比 | 52.5% | 51.8% |
| 每股收益（稀释后） | $-0.09 | $-3.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMSBDSX
| Q4 25 | $7.7M | $28.8M | ||
| Q3 25 | $7.2M | $21.8M | ||
| Q2 25 | $7.1M | $20.0M | ||
| Q1 25 | $6.1M | $18.0M | ||
| Q4 24 | $9.1M | $20.4M | ||
| Q3 24 | $7.0M | $18.2M | ||
| Q2 24 | $7.1M | $17.9M | ||
| Q1 24 | $5.2M | $14.8M |
净利润AMSBDSX
| Q4 25 | $-631.0K | $-4.0M | ||
| Q3 25 | $-17.0K | $-8.7M | ||
| Q2 25 | $-280.0K | $-11.5M | ||
| Q1 25 | $-625.0K | $-11.1M | ||
| Q4 24 | $-1.3M | $-8.3M | ||
| Q3 24 | $-207.0K | $-10.3M | ||
| Q2 24 | $3.6M | $-10.8M | ||
| Q1 24 | $119.0K | $-13.6M |
毛利率AMSBDSX
| Q4 25 | 11.7% | — | ||
| Q3 25 | 22.1% | — | ||
| Q2 25 | 23.1% | — | ||
| Q1 25 | 15.4% | — | ||
| Q4 24 | 35.3% | — | ||
| Q3 24 | 19.6% | — | ||
| Q2 24 | 35.0% | — | ||
| Q1 24 | 41.1% | — |
营业利润率AMSBDSX
| Q4 25 | -18.1% | -6.8% | ||
| Q3 25 | -4.8% | -32.4% | ||
| Q2 25 | -7.7% | -48.6% | ||
| Q1 25 | -21.3% | -50.9% | ||
| Q4 24 | -20.2% | -32.5% | ||
| Q3 24 | -12.7% | -47.3% | ||
| Q2 24 | -0.0% | -46.0% | ||
| Q1 24 | -1.6% | -74.4% |
净利率AMSBDSX
| Q4 25 | -8.2% | -13.8% | ||
| Q3 25 | -0.2% | -40.0% | ||
| Q2 25 | -4.0% | -57.3% | ||
| Q1 25 | -10.2% | -61.8% | ||
| Q4 24 | -14.6% | -40.4% | ||
| Q3 24 | -3.0% | -56.5% | ||
| Q2 24 | 51.0% | -60.3% | ||
| Q1 24 | 2.3% | -91.9% |
每股收益（稀释后）AMSBDSX
| Q4 25 | $-0.09 | $-3.35 | ||
| Q3 25 | $0.00 | $-1.16 | ||
| Q2 25 | $-0.04 | $-0.08 | ||
| Q1 25 | $-0.10 | $-0.08 | ||
| Q4 24 | $-0.21 | $-5.02 | ||
| Q3 24 | $-0.03 | $-1.40 | ||
| Q2 24 | $0.55 | $-0.08 | ||
| Q1 24 | $0.02 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5M | $19.0M |
| 总债务越低越好 | $17.4M | $50.0M |
| 股东权益账面价值 | $24.0M | $-2.5M |
| 总资产 | $55.5M | $87.5M |
| 负债/权益比越低杠杆越低 | 0.72× | — |
8季度趋势，按日历期对齐
现金及短期投资AMSBDSX
| Q4 25 | $3.5M | $19.0M | ||
| Q3 25 | $5.1M | $16.6M | ||
| Q2 25 | $11.1M | $20.7M | ||
| Q1 25 | $11.2M | $17.6M | ||
| Q4 24 | $11.0M | $26.2M | ||
| Q3 24 | $13.8M | $31.4M | ||
| Q2 24 | $14.2M | $42.2M | ||
| Q1 24 | $12.8M | $11.5M |
总债务AMSBDSX
| Q4 25 | $17.4M | $50.0M | ||
| Q3 25 | $18.2M | $50.0M | ||
| Q2 25 | $19.1M | $50.0M | ||
| Q1 25 | $19.9M | $40.0M | ||
| Q4 24 | $20.4M | $40.0M | ||
| Q3 24 | $14.4M | $40.0M | ||
| Q2 24 | $15.1M | $40.1M | ||
| Q1 24 | $15.6M | $40.1M |
股东权益AMSBDSX
| Q4 25 | $24.0M | $-2.5M | ||
| Q3 25 | $24.6M | $-1.7M | ||
| Q2 25 | $24.5M | $1.1M | ||
| Q1 25 | $24.6M | $11.1M | ||
| Q4 24 | $25.2M | $20.9M | ||
| Q3 24 | $26.4M | $27.9M | ||
| Q2 24 | $26.5M | $36.3M | ||
| Q1 24 | $22.8M | $-5.5M |
总资产AMSBDSX
| Q4 25 | $55.5M | $87.5M | ||
| Q3 25 | $59.6M | $88.7M | ||
| Q2 25 | $63.5M | $87.7M | ||
| Q1 25 | $63.3M | $86.2M | ||
| Q4 24 | $60.2M | $97.2M | ||
| Q3 24 | $63.3M | $102.7M | ||
| Q2 24 | $60.8M | $115.8M | ||
| Q1 24 | $50.1M | $87.2M |
负债/权益比AMSBDSX
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.74× | — | ||
| Q2 25 | 0.78× | 43.95× | ||
| Q1 25 | 0.81× | 3.62× | ||
| Q4 24 | 0.81× | 1.92× | ||
| Q3 24 | 0.54× | 1.44× | ||
| Q2 24 | 0.57× | 1.10× | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-704.0K | $778.0K |
| 自由现金流经营现金流 - 资本支出 | $-2.7M | $692.0K |
| 自由现金流率自由现金流/营收 | -34.8% | 2.4% |
| 资本支出强度资本支出/营收 | 25.7% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.5M | $-23.5M |
8季度趋势，按日历期对齐
经营现金流AMSBDSX
| Q4 25 | $-704.0K | $778.0K | ||
| Q3 25 | $1.7M | $-8.9M | ||
| Q2 25 | $-372.0K | $-6.6M | ||
| Q1 25 | $2.5M | $-8.6M | ||
| Q4 24 | $274.0K | $-4.1M | ||
| Q3 24 | $472.0K | $-10.7M | ||
| Q2 24 | $1.3M | $-18.6M | ||
| Q1 24 | $-1.9M | $-15.3M |
自由现金流AMSBDSX
| Q4 25 | $-2.7M | $692.0K | ||
| Q3 25 | $-2.0M | $-8.9M | ||
| Q2 25 | $-2.3M | $-6.6M | ||
| Q1 25 | $-1.5M | $-8.7M | ||
| Q4 24 | $-4.4M | $-4.9M | ||
| Q3 24 | $-407.0K | $-10.9M | ||
| Q2 24 | $70.0K | $-20.5M | ||
| Q1 24 | $-3.0M | $-15.5M |
自由现金流率AMSBDSX
| Q4 25 | -34.8% | 2.4% | ||
| Q3 25 | -28.3% | -41.0% | ||
| Q2 25 | -32.1% | -33.1% | ||
| Q1 25 | -24.7% | -48.3% | ||
| Q4 24 | -48.4% | -24.2% | ||
| Q3 24 | -5.8% | -60.1% | ||
| Q2 24 | 1.0% | -114.3% | ||
| Q1 24 | -58.4% | -104.9% |
资本支出强度AMSBDSX
| Q4 25 | 25.7% | 0.3% | ||
| Q3 25 | 51.6% | 0.2% | ||
| Q2 25 | 26.9% | 0.3% | ||
| Q1 25 | 65.7% | 0.4% | ||
| Q4 24 | 51.4% | 4.1% | ||
| Q3 24 | 12.6% | 1.3% | ||
| Q2 24 | 17.2% | 10.7% | ||
| Q1 24 | 22.7% | 1.6% |
现金转化率AMSBDSX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.36× | — | ||
| Q1 24 | -15.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMS
| Direct Patient Services | $4.0M | 51% |
| Rental Income From Medical Services | $2.7M | 35% |
| Pbrt Services | $1.2M | 15% |
BDSX
| Diagnostic Tests | $25.1M | 87% |
| Development Services | $3.6M | 13% |
